PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

August 05, 2010 | ISSUE NUMBER 160 VOL 8

Regulatory
NicOx Shutters HQ After Approval Fail
In the wake of FDA’s refusal to approve the lead drug in NicOx’s pipeline, the French firm has decided to close its US headquarters. Is NicOx the latest victim of stricter US regulations?

Advertisement:
Capgemini
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop. Click here

Strategy
Options for Oncologists Get Tougher
NCCN survey shows growing pressure on cancer practice bottom lines.

Legal
Mass Gift Ban Repeal Efforts Fizzle
Opponents in Massachusetts beat back an effort to repeal the state’s ban on most gifts to healthcare providers from pharmaceutical and medical device companies. The year-old ban is considered one of the most restrictive in the country.

M&A
5 Years Later: Conatus Acquires Idun
Former Idun Pharma team buys back company from Pfizer.

New & Noteworthy
Road Map for REMS
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.

// Watson Pharmaceuticals hired Sigurdur Oli Olafsson as executive vice president, global generics; and promoted Robert Stewart to executive vice president, global operations. // Paul McGarty was appointed president of Lupin Pharmaceuticals. // Celsion named Robert W. Hooper to its board of directors. // Tengion appointed A. Brian Davis CFO. // Aragon Pharmaceuticals named Richard A. Heyman CEO.

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA?

Protection from Patent Dependence

Actos Cashes In On Avandia Safety Concerns

ATMI Expands Bloomington, Minnesota, Manufacturing Facility

Personalized Medicine: A Fundamental Primer


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.